Pfizer

RUXIENCE

Manufacturer:

Pfizer

Ruxience HCPCS:

Q5119

HCPCS Code Descriptor:

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Category:

Q Code

Ruxience NDCs:

00069-0249-01, 00069-0238-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Ruxience:

RUXIENCE is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5119 is aligned to the drug RUXIENCE.

Ruxience targets the CD20 protein in red blood cells and is used to treat certain types of cancer and autoimmune disorders. Ruxience is manufactured by Pfizer and is biosimilar to the medication Rituxan (J9311). Ruxience was aligned to the HCPCS code Q5119 in July 2020. Patient assistance programs for this medication can be found through Pfizer enCompass.

ACCESS PRICING AND MORE BY REGISTERING

Q5119 Added Date:

July 1, 2020

Q5119 Effective Date:

July 1, 2020

Q5119 Termination Date:

HCPCS Active

Ruxience billing and coding information can be found through Pfizer at the link below:
Ruxience patient assistance information can be found through Pfizer enCompass at the URL: https://www.pfizerencompass.com/
RUXIENCE prescribing information can be found at the link below:
Information regarding RUXIENCE’s side effects can be found at MedlinePlus